This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Evolus, Inc. (EOLS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Evolus, Inc. (EOLS) delivered earnings and revenue surprises of -12.50% and 2.32%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Evolus, Inc. (EOLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aurora Cannabis (ACB) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Aurora Cannabis' (ACB) sturdy consumer cannabis sales are likely to have benefited its performance in the fiscal third quarter.
Schrodinger (SDGR) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Schrodinger's (SDGR) first-quarter results are likely to reflect benefits from collaborations.
Why Evolus (EOLS) Might Surprise This Earnings Season
by Zacks Equity Research
Evolus (EOLS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
What's in Store for Asensus Surgical's (ASXC) Q1 Earnings?
by Zacks Equity Research
Asensus Surgical's (ASXC) first-quarter results are likely to reflect benefits from regulatory approvals and collaboration.
Evolus, Inc. (EOLS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
by Zacks Equity Research
Evolus, Inc. (EOLS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Evolus, Inc. (EOLS) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Evolus, Inc. (EOLS) delivered earnings and revenue surprises of -231.82% and -0.11%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Science Applications (SAIC) 4Q Earnings?
by Zacks Equity Research
Science Applications' (SAIC) fourth-quarter fiscal 2021 performance is likely to reflect benefits from new contract wins and acquisitions of Engility and Unisys Federal acquisition.
CuriosityStream (CURI) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
CuriosityStream's (CURI) fourth-quarter 2020 results are expected to reflect expanding subscriber base, driven by strong factual content portfolio.
Is a Surprise Coming for Evolus (EOLS) This Earnings Season?
by Zacks Equity Research
Evolus (EOLS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Do Options Traders Know Something About Evolus (EOLS) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Evolus (EOLS) stock based on the movements in the options market lately.
Are Options Traders Betting on a Big Move in Evolus (EOLS) Stock?
by Zacks Equity Research
Investors need to pay close attention to Evolus (EOLS) stock based on the movements in the options market lately.
Is the Options Market Predicting a Spike in Evolus (EOLS) Stock?
by Zacks Equity Research
Investors need to pay close attention to Evolus (EOLS) stock based on the movements in the options market lately.
Why Earnings Season Could Be Great for Evolus (EOLS)
by Zacks Equity Research
Evolus (EOLS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Biocept (BIOC) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Biocept (BIOC) is expected to have suffered in Q2 from reduced oncology practices and postponement of patient appointments.
Implied Volatility Surging for Evolus (EOLS) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Evolus (EOLS) stock based on the movements in the options market lately.
Implied Volatility Surging for Evolus (EOLS) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Evolus (EOLS) stock based on the movements in the options market lately.
Allergan (AGN) Surpasses Q4 Earnings and Sales Estimates
by Kinjel Shah
Botox, Juvederm fillers and Vraylar drive Allergan's (AGN) fourth-quarter sales, making up for loss of exclusivity on some brands and lower sales of eye drug, Restasis.
Allergan (AGN) Shareholders Approve Acquisition by AbbVie
by Kinjel Shah
Allergan's (AGN) shareholders give green signal to its pending merger with AbbVie for a transaction value of nearly $63 billion.
What's in Store for Flexible Solutions (FSI) in Q2 Earnings?
by Zacks Equity Research
Our proven model does not show that Flexible Solutions (FSI) is likely to beat estimates this quarter.
Barrick (GOLD) to Post Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Strong performances from Loulo-Gounkoto and Veladero likely to drive Barrick's (GOLD) Q2 results.
Advance Auto Parts (AAP) to Post Q2 Earnings: What's Up?
by Zacks Equity Research
Advance Auto Parts (AAP) Q2 results to gain on footprint expansion. However, high capital expenditures and tough competition make surprise prediction difficult.
4 Medical Product Stocks Set to Beat This Earnings Season
by Urmimala Biswas
Here we discuss four medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.
Will Evolus Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Evolus.